SUBSCRIPTION AGREEMENTSubscription Agreement • September 1st, 2006 • Imvision Therapeutics Inc. • Nevada
NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
Employment ContractImvision Therapeutics Inc. • September 1st, 2006 • Hanover
subject to the provisions of the Shareholders’ Resolution of January 28, 2005, the following employment contract is concluded for the position of General Manager.
Service AgreementService Agreement • September 1st, 2006 • Imvision Therapeutics Inc.
ImVisioN runs its business on the premises of the current main office of DBVN. In return for remuneration, DBVN provides premises and staff infrastructure for this purpose within the framework described in the following, and can provide further services on request.
Patent Purchasing Agreement and Backlicense Agreement between Productomics AG, Promenade 132 A, CH-7260 Davos-Dorf, SwitzerlandPatent Purchasing Agreement and Backlicense Agreement • September 1st, 2006 • Imvision Therapeutics Inc.
The Seller is hereby granted all rights of registration of patents GB 0309345.7 and WO 2004/094639 A2 entitled “A recombinant Allergen”, requiring the use of the Fel d1 recombined allergen (fusion molecule in field 1 chain 2 and chain 1) in the diagnosis and treatment of cat allergies.
RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • September 1st, 2006 • Imvision Therapeutics Inc. • Nevada
NEXTECH VENTURE LP and IMVISION THERAPEUTICS INC. and IMVISION GmbHEquity Share Purchase Agreement • September 1st, 2006 • Imvision Therapeutics Inc. • Nevada
NEXTECH VENTURE LP, a Delaware limited partnership, whose principal office is at 47 Hulfish Street, Suite 420, Princeton, New Jersey, 08542, United States
Amendment to Employment AgreementImvision Therapeutics Inc. • September 1st, 2006
Due to the subscription of Prof. Dr. Horst Rose to purchase 1.300.000 shares of ImVisioN Therapeutics Inc. at a purchase price of $ 0,001 per share in the course of a private placement completed on June 30th 2006, ImVisioN GmbH and Dr. Martin Steiner agree to amend the employment agreement dated March 30th 2005 as follows:
ContractAgreement • September 1st, 2006 • Imvision Therapeutics Inc.
ImVisioN GmbH, a company duly existing and organised under the laws of the Federal Republic of Germany and having its registered offices at Feodor-Lynen-Str. 5, 30625 Hannover, Federal Republic of Germany
AGREEMENT Strain Development, Process Development and Manufacturing of Clinical Grade Material of a Fel d1 MAT Fusion Protein between ImVisioN GmbH, Feodor Lynen Strasse 5, Hannover (IVN) and Strathmann Biotec AG, Habichthorst 30, 22459 Hamburg,...Agreement • September 1st, 2006 • Imvision Therapeutics Inc.
ImVisioN GmbH is a biotechnology company based in Hannover, Germany, and focused on the development of novel immuntherapies based on its MAT (Modular-Antigen-Transporter) technology platform to treat allergic diseases, (chronic) infectious diseases and possibly cancer.
Amendment to Employment AgreementImvision Therapeutics Inc. • September 1st, 2006
Due to the subscription of Dr. Martin Steiner to purchase 1.300.000 shares of ImVisioN Therapeutics Inc. at a purchase price of $ 0,001 per share in the course of a private placement completed on June 30th 2006, ImVisioN GmbH and Dr. Martin Steiner agree to amend the employment agreement dated March 30th 2005 as follows:
Patent and Know-how Purchasing Agreement between BioVision AG, Feodor-Lynen Straße 5, D-30625 Hanover, GermanyPurchasing Agreement • September 1st, 2006 • Imvision Therapeutics Inc.
The Seller is hereby granted all rights of registration of patent WO 2004/035793 entitled “Modular antigen transporter molecules for modulating immune reactions, associated constructs, methods and uses thereof”, as well as of patent EP 1 400 114 A entitled “Modular antigen transporter molecules (MAT molecules) for modulating immune reactions, associated constructs, methods and uses thereof”.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • September 1st, 2006 • Imvision Therapeutics Inc. • California
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of February 8, 2006 (the “Effective Date”) by and between MANNKIND CORPORATION, a Delaware corporation (“MannKind”), having an address of 28903 North Avenue Paine, Valencia, CA 91355, USA, and IMVISION GMBH, a company organized under the laws of Germany (“ImVisioN”), having an address of Feodor-Lynen-Straße 5, D-30625 Hannover, Germany.
SUBSCRIPTION AGREEMENT IMVISION THERAPEUTICS INC.Subscription Agreement • September 1st, 2006 • Imvision Therapeutics Inc. • Nevada
SUBSCRIPTION AGREEMENT (the “Subscription Agreement”) made effective as of the 30th day of June, 2006 between ImVisioN Therapeutics Inc., a Nevada corporation (the "Company") and the undersigned subscriber (the "Subscriber").
